
Proceedings Paper
Direct detection of cancer biomarkers using plasmonics-based Inverse Molecular Sentinel (iMS) nanobiosensorsFormat | Member Price | Non-Member Price |
---|---|---|
$17.00 | $21.00 |
Paper Abstract
Development of simple techniques for detection of nucleic acids is essential for clinical diagnostics. MicroRNA (miRNA) have been identified as potential biomarkers in early detection of various diseases, including esophageal adenocarcinoma (EAC) and Barrett’s esophagus (BE). However, these small molecules have not been adopted into clinical practice because of challenging aspects in the lab. The technology described herein is a label-free nanoprobe referred to as “inverse molecular sentinel” (iMS) for gastrointestinal cancer diagnosis using surface-enhanced Raman scattering (SERS) detection. The results of this study provide evidence supporting the robust iMS method for miRNA sensing without the need for PCR.
Paper Details
Date Published: 9 September 2019
PDF: 10 pages
Proc. SPIE 11087, Biosensing and Nanomedicine XII, 1108702 (9 September 2019); doi: 10.1117/12.2529832
Published in SPIE Proceedings Vol. 11087:
Biosensing and Nanomedicine XII
Hooman Mohseni; Massoud H. Agahi, Editor(s)
PDF: 10 pages
Proc. SPIE 11087, Biosensing and Nanomedicine XII, 1108702 (9 September 2019); doi: 10.1117/12.2529832
Show Author Affiliations
Bridget M. Crawford, Duke Univ. (United States)
Hsin-Neng Wang, Duke Univ. (United States)
Michelle L. Bowie, Duke Univ. Medical Ctr. (United States)
Hsin-Neng Wang, Duke Univ. (United States)
Michelle L. Bowie, Duke Univ. Medical Ctr. (United States)
Victoria L. Seewaldt, Duke Univ. Medical Ctr. (United States)
Tuan Vo-Dinh, Duke Univ. (United States)
Tuan Vo-Dinh, Duke Univ. (United States)
Published in SPIE Proceedings Vol. 11087:
Biosensing and Nanomedicine XII
Hooman Mohseni; Massoud H. Agahi, Editor(s)
© SPIE. Terms of Use
